When we look at Bitcoin’s price, the concern extends to the altcoins as well; however, it should also extend to the companies associated with BTC-related activities.
In line with the same, BeInCrypto has analysed three Bitcoin mining companies’ stock performance and what lies ahead for them.
BitMine Immersion Technologies (BMNR)
BMNR has dropped 24% this week and trades at $30.95. Despite the decline, Bitmine has continued accumulating ETH, adding 54,156 ETH worth more than $170 million over the past seven days. This signals a strong long-term conviction from the company.
The RSI is nearing the oversold zone, which often precedes a reversal. If conditions stabilize, BMNR could rebound from the $30.88 support and climb toward $34.94 or even $37.27, offering relief after a week of heavy losses.
Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.
If Bitcoin weakens further, BMNR may follow the broader downturn. A deeper decline could send the stock below $27.80, with potential downside extending to $24.64. This would invalidate the bullish outlook and signal intensified bearish momentum.
Bitdeer Technologies Group (BTDR)
Bitdeer has recorded some of the steepest losses among Bitcoin mining stocks, falling 53% over seven sessions. The share price now sits at $10.63, reflecting intense selling pressure as broader market weakness continues to weigh on mining companies.
BTDR’s RSI is deep in the oversold zone, signaling conditions that often precede a reversal. If buyers step in, the stock could rebound from $9.56 and move toward $11.92, with potential upside extending to $15.24 if momentum strengthens.
If market conditions fail to improve, BTDR could continue its decline. A breakdown below $9.56 may drive the price toward $7.96. This would invalidate the bullish outlook and signal an extended downside for the mining firm.
HIVE Digital Technologies Ltd. (HIVE)
Bitcoin mining company HIVE has dropped 29% over the past week but now trades at $3.56 after gaining 7.5% today. The surge follows the company’s announcement of 285% revenue growth in Q2, which has boosted investor confidence despite recent volatility.
This strong performance could fuel a broader recovery and lift HIVE toward $4.04. Restoring recent losses would require a move to $5.09. Reaching this target may take time, but it remains possible if momentum and sentiment continue improving.
If the stock fails to capitalize on the company’s earnings strength, HIVE may resume its decline. A drop toward the $3.00 support level or lower would invalidate the bullish thesis and signal renewed weakness.
Bitrue